CD133 and BMI1 expressions and its prognostic role in primary glioblastoma. J Genet 2015 Dec;94(4):689-96
Date
12/23/2015Pubmed ID
26690524DOI
10.1007/s12041-015-0583-0Scopus ID
2-s2.0-84953637077 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Glioblastoma is the most common malignant brain tumour, generated by bulk of malignant cancer stem cells, which express various stem cell factors like CD133, BMI1 and nestin. There are several studies which show the importance of CD133 in cancer, but the function and interaction with other major oncogenes and tumour suppressor genes is still not understood. This study aimed to analyse the expression of CD133 mRNA and its correlations with BMI1 protein expression and TP53 mutations in newly diagnosed glioblastoma patients and its role in prognosis. Overexpression of CD133 mRNA and BMI1 protein was found in 47.6 and 76.2% patients respectively and TP53 mutations was seen in 57.1% of patients in our study.There was no correlation among TP53 mutations and expressions of CD133 and BMI1. We found that high level of BMI1 expression was favourable for the patient survival (P=0.0075) and high CD133 mRNA expression was unfavourable for the patient survival (P=0.0226).CD133 mRNA and BMI1 protein expression could independently predict the glioblastoma patient survival in multivariate analysis. In conclusion, the overexpression of these stem cell markers is a common event in glioblastoma progression and could be used as potential prognostic markers.
Author List
Sibin MK, Lavanya CH, Bhat DI, Rao N, Geethashree N, Vibhuti W, Chetan GKAuthor
Lavanya Choppavarapu PhD Research Scientist I in the Data Science Institute department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AC133 AntigenAntigens, CD
Brain Neoplasms
Female
Glioblastoma
Glycoproteins
Humans
Male
Middle Aged
Peptides
Polycomb Repressive Complex 1
Prognosis
